云顶新耀医药科技有限公司 EVEREST MEDICINES
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients 2023-09-28 07:38
Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets 2023-09-21 07:05
Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis 2023-09-20 08:26
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy 2023-08-25 08:15
Everest Medicines Announces Interim Results for First Half of 2023 2023-08-24 08:15
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy 2023-08-21 08:20
Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet 2023-08-18 08:41
Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI) 2023-08-15 20:19
Everest Medicines to Announce First Half 2023 Financial Results on August 24, 2023 2023-08-09 08:06
Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study 2023-08-01 08:47
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China 2023-07-27 08:10
Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA ) 2023-06-21 08:15
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer 2023-06-16 07:45
Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia 2023-05-17 07:48
Nefecon Included in the Reimbursement Drug List of "Beijing Puhui Health Insurance Program" as a First-in-Disease Therapy for IgA Nephropathy 2023-05-12 07:40
Everest Medicines Launches Nefecon in China's Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy 2023-04-24 07:44
Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China 2023-04-19 08:12
Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy 2023-04-06 07:30
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022 2023-03-31 07:30
Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves 2023-03-27 08:15
1 2 3 4 5 7